Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2021

Segment Reporting [Abstract]

Schedule of Segment Information

The tables below present segment information reconciled to total Company loss from operations, with segment operating loss including gross profit less direct research and development expenses and direct selling, general and administrative expenses to the extent specifically identified by segment:

	Three Months Ended March 31, 2021
	(in thousands)
	Water Filtration			Pathogen Detection			Renal Products			Nephros, Inc. Consolidated
Total net revenues	$	2,736		$	-		$	-		$	2,736
Gross margin		1,587			-			-			1,587
Research and development expenses		294			119			143			556
Depreciation and amortization expense		50			-			-			50
Selling, general and administrative expenses		1,876			101			22			1,999
Change in fair value of contingent consideration		-			-			-			-
Total operating expenses		2,220			220			165			2,605
Loss from operations	$	(633	)	$	(220	)	$	(165	)	$	(1,018	)

	Three Months Ended March 31, 2020
	(in thousands)
	Water Filtration			Pathogen Detection			Renal Products			Nephros, Inc. Consolidated
Total net revenues	$	2,511		$	18		$	-		$	2,529
Gross margin		1,480			11			-			1,491
Research and development expenses		310			52			201			563
Depreciation and amortization expense		46			-			-			46
Selling, general and administrative expenses		1,715			125			110			1,950
Change in fair value of contingent consideration		(42	)		-			-			(42	)
Total operating expenses		2,029			177			311			2,517
Loss from operations	$	(549	)	$	(166	)	$	(311	)	$	(1,026	)